IDYA
IDEAYA Biosciences, Inc.
$28.98
+0.49%
$2.5B
No data for this timeframe.
Vol
Market Cap$2.5B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders50 funds
Inst. Value$2.2B
Inst. Activity8 buys / 6 sells
Insider Activity1B / 0S
Insider Net $$1.6M
Reddit Sentiment50° Neutral
SEC Reports8
Recent Activity
Jun 10, 2026
SEC
IDEAYA Biosciences completed a follow-on public offering on June 10, 2026, selling 7,222,225 shares of common stock and
8-K — Impact 6/10
Jun 9, 2026
SEC
IDEAYA Biosciences is raising approximately $281.3 million in net proceeds through a public offering of 5,555,556 shares
424B5 — Impact 6/10
Jun 8, 2026
SEC
IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M underwritten public offering of common stock and pre-
424B5 — Impact 6/10
Mar 2, 2026
Insider
Stein Jeffrey bought 50,000 shares
Director @ $32.96 ($1.6M)
Jan 30, 2026
Insider
WHITE MICHAEL ANTHONY was granted 190,000 shares
Chief Scientific Officer
Jan 30, 2026
Insider
Beaupre Darrin was granted 175,000 shares
Chief Medical Officer
Inst.
MORGAN STANLEY — ADD
1,860,453 shares ($62.0M)
Inst.
DIMENSIONAL FUND ADVISORS LP — ADD
1,333,478 shares ($44.4M)
Price Targets
$51.93
+79.2% upside
Strong Buy
Current $28.98
Low $36.00
Median $50.00
High $66.00
15 analysts
$36.00
$66.00
Analyst Ratings
9Strong Buy
13Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 12, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Jun 2, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Apr 14, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
| Apr 14, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.06 | $-1.27 — $-0.75 | -21% YoY | 15 |
| Next Q | $-1.07 ▲ +2.9% | $-1.26 — $-0.72 | -180% YoY | 15 |
| Current FY | $-4.33 ▲ +2.3% | $-5.00 — $-3.63 | -238% YoY | 15 |
| Next FY | $-3.72 ▼ -0.5% | $-4.59 — $-1.29 | 14% YoY | 15 |
Latest Reports
BEARISH
8-K
6/10
IDEAYA Biosciences completed a follow-on public offering on June 10, 2026, selling 7,222,225 shares of common stock and
Jun 10, 2026
BEARISH
424B5
6/10
IDEAYA Biosciences is raising approximately $281.3 million in net proceeds through a public offering of 5,555,556 shares
Jun 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| FMR LLC | $438.9M | — |
| BlackRock, Inc. | $281.3M | — |
| JANUS HENDERSON GROUP PLC | $242.0M | — |
| Capital Research Global Investors | $172.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 2, 2026 | Stein Jeffrey | BUY | $1.6M |
| Jan 30, 2026 | WHITE MICHAEL | A | $0.00 |
| Jan 30, 2026 | Beaupre Darrin | A | $0.00 |
| Jan 30, 2026 | DORMAN STUART | A | $0.00 |
| Jan 30, 2026 | Snyder Douglas | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $2.2B total value (66,873,206 shares) as of 2026-Q1. Top holders: NOMURA, FMR, BlackRock,. Net buying activity: 8 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | FMR LLC | 13,172,103 | $438.9M | 19.7% | — |
| 3 | BlackRock, Inc. | 8,442,133 | $281.3M | 12.6% | — |
| 4 | JANUS HENDERSON GROUP PLC | 7,265,253 | $242.0M | 10.9% | — |
| 5 | Capital Research Global Investors | 5,163,543 | $172.0M | 7.7% | — |
| 6 | BAKER BROS. ADVISORS LP | 3,946,515 | $131.5M | 5.9% | ADD +54.6% |
| 7 | STATE STREET CORP | 3,781,167 | $126.0M | 5.7% | ADD +27.6% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3,732,422 | $124.4M | 5.6% | — |
| 9 | FEDERATED HERMES, INC. | 2,987,107 | $99.5M | 4.5% | TRIM -26.6% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,823,500 | $94.1M | 4.2% | DOUBLED +134.2% |
| 11 | MORGAN STANLEY | 1,860,453 | $62.0M | 2.8% | ADD +48.6% |
| 12 | GOLDMAN SACHS GROUP INC | 1,655,617 | $55.2M | 2.5% | — |
| 13 | DIMENSIONAL FUND ADVISORS LP | 1,333,478 | $44.4M | 2.0% | ADD +42.0% |
| 14 | BNP Paribas Asset Management Holding S.A. | 1,101,145 | $36.7M | 1.6% | ADD +57.8% |
| 15 | BANK OF AMERICA CORP /DE/ | 942,091 | $31.4M | 1.4% | — |
| 16 | VANGUARD PORTFOLIO MANAGEMENT LLC | 745,593 | $24.8M | 1.1% | — |
| 17 | Pictet Asset Management Holding SA | 715,906 | $23.9M | 1.1% | TRIM -28.9% |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 715,527 | $23.8M | 1.1% | — |
| 19 | CITADEL ADVISORS LLC | 679,400 | $22.6M | 1.0% | TRIM -27.9% |
| 20 | VANGUARD FIDUCIARY TRUST CO | 561,563 | $18.7M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 1,252,404 | 1,860,453 | +48.6% | $62.0M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 938,857 | 1,333,478 | +42.0% | $44.4M | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 697,925 | 1,101,145 | +57.8% | $36.7M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 1,844,556 | 327,901 | -82.2% | $10.9M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 596,483 | 208,345 | -65.1% | $6.9M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 48,920 | 177,272 | +262.4% | $5.9M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 9,683 | 134,932 | +1293.5% | $4.5M | 2026-Q1 |
| Invesco Ltd. | TRIM | 238,314 | 111,112 | -53.4% | $3.7M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 126,362 | 86,684 | -31.4% | $2.9M | 2026-Q1 |
| Mitsubishi UFJ Asset Management Co., Ltd. | DOUBLED | 5,191 | 66,066 | +1172.7% | $2.2M | 2026-Q1 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | TRIM | 171,278 | 65,944 | -61.5% | $2.1M | 2026-Q1 |
| Vanguard Personalized Indexing Management, LLC | ADD | 10,507 | 15,614 | +48.6% | $520.3K | 2026-Q1 |
| GROUP ONE TRADING LLC | DOUBLED | 468 | 7,992 | +1607.7% | $266.3K | 2026-Q1 |
| Rockefeller Capital Management L.P. | NEAR_EXIT | 3,795 | 532 | -86.0% | $17.7K | 2026-Q1 |
| STATE STREET CORP | ADD | 3,240,934 | 4,134,641 | +27.6% | $142.9M | 2025-Q4 |
| FEDERATED HERMES, INC. | TRIM | 4,625,850 | 3,395,771 | -26.6% | $117.4M | 2025-Q4 |
| Point72 Asset Management, L.P. | TRIM | 3,815,704 | 1,844,556 | -51.7% | $63.8M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 497,048 | 938,857 | +88.9% | $32.5M | 2025-Q4 |
| Pictet Asset Management Holding SA | TRIM | 1,032,999 | 734,335 | -28.9% | $25.4M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | ADD | 380,311 | 596,483 | +56.8% | $20.6M | 2025-Q4 |
| Nuveen, LLC | ADD | 208,759 | 374,007 | +79.2% | $12.9M | 2025-Q4 |
| Invesco Ltd. | ADD | 124,196 | 238,314 | +91.9% | $8.2M | 2025-Q4 |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 228,889 | 163,407 | -28.6% | $5.6M | 2025-Q4 |
| Rafferty Asset Management, LLC | ADD | 93,152 | 126,362 | +35.7% | $4.4M | 2025-Q4 |
| ALPS ADVISORS INC | ADD | 42,150 | 71,789 | +70.3% | $2.5M | 2025-Q4 |
8 unique insiders with 12 transactions. Net insider value: $1.6M ($1.6M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Stein Jeffrey | Director | BUY | 50,000 | $32.96 | $1.6M |
| Jan 30, 2026 | WHITE MICHAEL ANTHONY | Chief Scientific Officer | AWARD | 190,000 | — | — |
| Jan 30, 2026 | Beaupre Darrin | Chief Medical Officer | AWARD | 175,000 | — | — |
| Jan 30, 2026 | DORMAN STUART | Chief Commercial Officer | AWARD | 155,000 | — | — |
| Jan 30, 2026 | Snyder Douglas B. | SVP, General Counsel | AWARD | 130,000 | — | — |
| Jan 30, 2026 | Ruiz Briseno Andres | See Remarks | AWARD | 80,000 | — | — |
| Jan 30, 2026 | Hata Yujiro S | President and CEO | AWARD | 600,000 | — | — |
| Jan 30, 2026 | Bleharski Joshua | Chief Financial Officer | AWARD | 170,000 | — | — |
| Nov 28, 2025 | Ruiz Briseno Andres | See Remarks | AWARD | 1,253 | $16.91 | $21.2K |
| Nov 28, 2025 | Snyder Douglas B. | SVP, General Counsel | AWARD | 1,041 | $16.91 | $17.6K |
| May 30, 2025 | Snyder Douglas B. | SVP, General Counsel | AWARD | 1,039 | $16.91 | $17.6K |
| Nov 29, 2024 | Ruiz Briseno Andres | See Remarks | AWARD | 682 | $23.26 | $15.9K |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 1 mixed, 3 neutral. Avg impact: 5.1/10.
BEARISH
8-K
6/10
IDEAYA Biosciences completed a follow-on public offering on June 10, 2026, selling 7,222,225 shares
Jun 10, 2026
BEARISH
424B5
6/10
IDEAYA Biosciences is raising approximately $281.3 million in net proceeds through a public offering
Jun 9, 2026
BEARISH
424B5
6/10
IDEAYA Biosciences filed a 424B5 prospectus supplement for a $300M underwritten public offering of c
Jun 8, 2026
NEUTRAL
8-K
4/10
IDEAYA announced a clinical collaboration with Roche to evaluate its PRMT5 inhibitor IDE892 in combi
Jun 3, 2026
NEUTRAL
8-K
2/10
IDEAYA Biosciences filed a new automatic shelf registration statement (Form S-3ASR) to replace its p
May 5, 2026
MIXED
424B5
5/10
IDEAYA Biosciences filed a prospectus supplement on May 5, 2026, for an at-the-market (ATM) offering
May 5, 2026
BULLISH
8-K
8/10
IDEAYA Biosciences announced positive Phase 2/3 clinical trial results for darovasertib in combinati
Apr 13, 2026
NEUTRAL
8-K
4/10
IDEAYA Biosciences announced a clinical collaboration with AstraZeneca to evaluate its investigation
Apr 9, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 25 analysts: 9 strong buy, 13 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$51.93 mean target
+79.2% upside
Strong Buy (1.41)
$36.00 Low
$66.00 High
| Metric | Value |
|---|---|
| Current Price | $28.98 |
| Target Low | $36.00 |
| Target Mean | $51.93 |
| Target Median | $50.00 |
| Target High | $66.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.41) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.06 | $-1.27 | $-0.75 | -20.9% | -0.4% | 1↑ 11↓ | $0.0B | 0.0% | 15 |
| Next Q 2026-09-30 |
$-1.07 | $-1.26 | $-0.72 | -180.3% | +2.9% | 1↑ 10↓ | $0.0B | -96.0% | 15 |
| Current FY 2026-12-31 |
$-4.33 | $-5.00 | $-3.63 | -238.3% | +2.3% | 2↑ 13↓ | $0.0B | -84.7% | 15 |
| Next FY 2027-12-31 |
$-3.72 | $-4.59 | $-1.29 | 14.1% | -0.5% | 2↑ 12↓ | $0.1B | 242.8% | 15 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.064 | |
| 7d ago | $-1.071 | +0.007 |
| 30d ago | $-1.060 | -0.004 |
| 60d ago | $-0.995 | -0.069 |
| 90d ago | $-0.991 | -0.073 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 12, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jun 2, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Apr 14, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 14, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 14, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 31, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Feb 19, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| Feb 18, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Feb 18, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 6, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 13 | 3 | 0 | 0 | 88% | |
| May 1, 2026 | 9 | 13 | 3 | 0 | 0 | 88% | |
| Apr 1, 2026 | 9 | 13 | 3 | 0 | 0 | 88% | |
| Mar 1, 2026 | 9 | 13 | 3 | 0 | 0 | 88% | |
| Feb 1, 2026 | 9 | 13 | 3 | 0 | 0 | 88% | |
| Jan 1, 2026 | 9 | 13 | 3 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Apr 13, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 11, 2026
short_volume
Short Volume: IDYA — 60.7% short (0.4M / 0.6M)
Short: 355,411 | Exempt: 2,574 | TRF Vol: 585,998 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: IDYA — 74.8% short (0.5M / 0.7M)
Short: 499,463 | Exempt: 6,084 | TRF Vol: 667,769 | Short Ratio: 74.8% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: IDYA — 61.0% short (1.1M / 1.8M)
Short: 1,072,204 | Exempt: 4,961 | TRF Vol: 1,758,954 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: IDYA — 56.7% short (0.7M / 1.3M)
Short: 729,433 | Exempt: 2,607 | TRF Vol: 1,287,551 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings_calendar
IDYA Q1 2026 Earnings Scheduled — 2026-05-04
Apr 23, 2026
short_volume
Short Volume: IDYA — 64.7% short (0.4M / 0.7M)
Short: 421,857 | Exempt: 0 | TRF Vol: 651,920 | Short Ratio: 64.7% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: IDYA — 60.5% short (0.4M / 0.6M)
Short: 365,974 | Exempt: 0 | TRF Vol: 604,946 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: IDYA — 57.3% short (0.6M / 1.0M)
Short: 593,764 | Exempt: 731 | TRF Vol: 1,035,359 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: IDYA — 56.0% short (1.3M / 2.2M)
Short: 1,250,267 | Exempt: 0 | TRF Vol: 2,232,753 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
short_interest
FTD: IDYA — 40,212 shares ($1.3M) failed to deliver
Settlement: 20260401, Price: $33.32, FTD Value: $1,339,863.84, IDEAYA BIOSCIENCES INC COM (DE
Mar 23, 2026
short_volume
Short Volume: IDYA — 70.4% short (0.4M / 0.6M)
Short: 432,101 | Exempt: 0 | TRF Vol: 613,426 | Short Ratio: 70.4% | Off-exchange volume (dark pool + OTC)
Feb 23, 2026
earnings_calendar
IDYA Q4 2025 Earnings After Market Close — 2026-02-23